5PSQ-115 Influence of the pharmacy in adherence to treatment in patients with multiple sclerosis

<h3>Background and Importance</h3> Ocrelizumab is an CD20-directed humanised monoclonal antibody, used in the treatment of primary progressive and relapsing multiple sclerosis. Is given every six months as a 600 mg intravenous infusion. <h3>Aim and Objectives</h3> The aim of the study was to monitor the prescribing appropriateness and therapeutic adherence of patients treated with Ocrelizumab in an Italian hospital. Since 01/01/2024, the prescription has been computerised and the preparation of the drug has been centralised in the Clinical Pharmacy laboratories present in the Hospital Pharmacy. This has speeded up the transmission and reception times of clinical information, reducing prescribing errors. The pharmacist of the Clinical Pharmacy Laboratory is responsible for the on-demand preparation of Ocrelizumab. <h3>Material and Methods</h3> Hospital prescriptions were analysed, from January 2020 to September 2024. A database has been created: data analysed were patient characteristics, clinical conditions and therapeutic indication entered by clinician, to verify prescriptive appropriateness. Therapeutic adherence was obtained comparing the clinical calendars of presumed administration (every six months) and the actual data in which the infusion was carried out. <h3>Results</h3> 117 patients were treated with ocrelizumab: 60,68% females males 39.32% males; average age 46 years. Patient adherence was 92.31%; 5,98% were not compliant with drug therapy due to suspension of therapy and 1,71% for irregular administration. To reduce prescribing errors and to evaluate the prescriptive appropriateness, collaborating with the clinician, computerised protocols were created, in which the clinical conditions of the patients were entered: all prescriptions were compliant than those provided in the technical data sheet. <h3>Conclusion and Relevance</h3> The analysis carried out confirms that the incidence of the disease follows the European trend, in which women are more affected than men, often adults under 50 years of age. Compliance with the treatment was particularly high: 92.31% of the sample examined regularly performed the treatment. Adherence is paramount to achieving therapeutic goals in multiple sclerosis: a therapy with an infrequent dosing schedule, twice a year, makes it easier to achieve. The data highlights the importance of implementing new technologies in the management of clinical activities of prescribing, preparation and administration of therapy, encouraging multidisciplinary collaboration between clinicians and hospital pharmacists, necessary to guarantee high standards of care performance. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest